Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

General Meeting

The General Meeting is Vivesto’s highest decision-making body, at which the shareholders exercise their voting rights.

At the Annual General Meeting (AGM), which must be held within six months of the end of the financial year, shareholders resolves on key issues, such as the adoption of income statements and balance sheets, appropriation of the company’s result, discharge from liability of members of the Board of Directors and the CEO, election of members of the Board of Directors and auditors and remuneration to the Board of Directors and the auditor.

No later than in conjunction with the publication of the third-quarter report, the date and place of the AGM is published on the company’s website. The notice of the AGM is published at the earliest six weeks, but no later than four weeks, before the date of the AGM.

In addition to the AGM, Extraordinary General Meetings may be convened when required.

Shareholders who are registered in Euroclear Sweden AB’s share register as of the record day and, by the date specified in the notice, have reported their intention to attend may participate and vote at the General Meeting, in person or by a representative.
Shareholders who wish to have a matter brought before the General Meeting must submit a written request to the Board of Directors. Normally, the request must be received by the Board of Directors no later than seven weeks prior to the General Meeting. Shareholders may submit their requests by e-mail to [email protected] or by ordinary mail to the following address:

Vivesto AB
Att: The Board of Directors
Box 3061
169 03 Solna
Sweden

All years
  • 2025
  • 2024
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2008
  • 2007
  • 2006
May 8, 2025

Annual General Meeting 2025

May 23, 2024

Annual General Meeting 2024

May 25, 2023

Annual General Meeting 2023

May 25, 2022

Annual General Meeting 2022

February 21, 2022

Extraordinary General Meeting 2022

October 20, 2021

Extraordinary General Meeting 2021

May 27, 2021

Annual General Meeting 2021

September 9, 2020

Annual General Meeting 2020

May 14, 2020

Extraordinary General Meeting 2020

November 6, 2019

Extraordinary General Meeting November 6, 2019

September 26, 2019

Annual General Meeting 2019

March 19, 2019

Extraordinary General Meeting 2019

September 25, 2018

Annual General Meeting 2018

September 25, 2017

Annual General Meeting 2017

June 2, 2017

Extraordinary General Meeting June 2017

November 21, 2016

Extraordinary General Meeting November 2016

September 26, 2016

Annual General Meeting 2016

September 28, 2015

Annual General Meeting 2015

May 28, 2015

Extraordinary General Meeting May 2015

September 29, 2014

Annual General Meeting 2014

September 30, 2013

Annual General Meeting 2013

September 24, 2012

Annual General Meeting 2012

September 30, 2011

Annual General Meeting 2011

September 28, 2010

Annual General Meeting 2010

September 11, 2008

Annual General Meeting 2008

September 7, 2007

Annual General Meeting 2007

September 15, 2006

Annual General Meeting 2006

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com